Related Experiment Video
Updated: Jul 17, 2026
07:41
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent
Amanda F Cashen1, Bruno Nervi, John DiPersio
1Washington University School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA. acashen@im.wustl.edu
Future Oncology (London, England)
|February 7, 2007
Summary
New methods are needed to improve stem cell collection for transplantation. AMD3100, a CXCR4 inhibitor, effectively mobilizes stem cells with minimal side effects, showing promise in clinical trials.
Area of Science:
- Hematology
- Stem Cell Biology
- Pharmacology
Background:
- Peripheral blood stem cells are crucial for transplantation.
- Current mobilization methods require improvement in efficiency and toxicity.
- Hematopoietic stem cell retention in bone marrow involves CXCR4 interactions.
Purpose of the Study:
- To evaluate AMD3100 as a novel agent for stem cell mobilization.
- To assess the efficacy and safety of AMD3100 in clinical trials.
- To compare the combination of AMD3100 and G-CSF with G-CSF alone for stem cell collection.
Main Methods:
- Clinical trials were conducted to assess AMD3100.
- AMD3100, a CXCR4 antagonist, was administered to patients.
- Stem cell mobilization was evaluated, including comparisons with G-CSF.
Main Results:
- AMD3100 rapidly mobilizes stem cells into peripheral blood.
- The agent demonstrated minimal side effects in early trials.
- Combining AMD3100 with G-CSF yielded higher progenitor cell collection than G-CSF alone.
Conclusions:
- AMD3100 is a promising agent for stem cell mobilization in transplantation.
- The combination therapy of AMD3100 and G-CSF enhances progenitor cell yield.
- AMD3100 offers a potentially safer and more effective mobilization strategy.
